Hepacivirus Infections is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hepacivirus Infections have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hepacivirus Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hepacivirus Infections overview
Hepacivirus infections are caused by a genus of positive-strand RNA viruses in the family Flaviviridae. The most common and well-known species is Hepacivirus C, which infects humans and causes hepatitis C, a chronic liver disease that can lead to cirrhosis and hepatocellular carcinoma. Hepacivirus C is transmitted by blood, sexual contact, and other routes. Other species of hepacivirus infect various vertebrates, such as horses, dogs, rodents, and bats. Equine hepacivirus (EqHV) is a model for studying hepacivirus infection and immunity in an immunocompetent host. Hepacivirus infections can be diagnosed by detecting viral RNA, antibodies, or antigens in blood samples. There is no vaccine for hepacivirus infections, but antiviral treatments can cure most cases of hepatitis C.
For a complete picture of PTSR and LoA scores for drugs in Hepacivirus Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
